The safety of solifenacin vesicare was appraised by comparing the incidence of drug adverse reactions in two groups.
通过用药不良反应发生率的对比分析，对其安全性进行评估。
Conclusions Solifenacin vesicare is a safer and more effective drug over tolterodine for the treatment of patients with OAB, and it could be served as a drug of first choice for treating OAB.
结论琥珀酸索利那新治疗OAB较托特罗定有更好的效果和更高的安全性，琥珀酸索利那新将可能成为治疗OAB的首选药物。
应用推荐